DexCom Historical Income Statement
DXCM Stock | USD 137.87 3.87 2.89% |
Historical analysis of DexCom income statement accounts such as Operating Income of 627.6 M or Ebit of 767.2 M can show how well DexCom Inc performed in making a profits. Evaluating DexCom income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of DexCom's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining DexCom Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether DexCom Inc is a good buy for the upcoming year.
DexCom |
About DexCom Income Statement Analysis
DexCom Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to DexCom shareholders. The income statement also shows DexCom investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
DexCom Income Statement Chart
DexCom Inc Income Statement is one of the three primary financial statements used for reporting DexCom's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of DexCom Inc revenue and expense. DexCom Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, DexCom's Net Income is very stable compared to the past year. As of the 25th of April 2024, Income Tax Expense is likely to grow to about 177.3 M, while Total Other Income Expense Net is likely to drop (2.1 M). Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of DexCom Inc. It is also known as DexCom overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from DexCom's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. At this time, DexCom's Net Income is very stable compared to the past year. As of the 25th of April 2024, Income Tax Expense is likely to grow to about 177.3 M, while Total Other Income Expense Net is likely to drop (2.1 M).
DexCom income statement Correlations
Click cells to compare fundamentals
DexCom Account Relationship Matchups
High Positive Relationship
High Negative Relationship
DexCom income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 60.3M | 84.7M | 102M | 18.6M | 20.3M | 15.5M | |
Other Operating Expenses | 1.3B | 1.6B | 2.2B | 2.5B | 3.0B | 3.2B | |
Operating Income | 142.3M | 299.5M | 175.4M | 391.2M | 597.7M | 627.6M | |
Ebit | 142.3M | 299.5M | 175.4M | 391.2M | 730.7M | 767.2M | |
Research Development | 273.5M | 359.9M | 604.2M | 484.2M | 505.8M | 531.1M | |
Ebitda | 164.5M | 382.7M | 277.4M | 416.9M | 916.7M | 962.5M | |
Total Operating Expenses | 789.2M | 980.6M | 1.4B | 1.5B | 1.7B | 1.8B | |
Net Income | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 568.6M | |
Income Tax Expense | 3.1M | (268.6M) | 19.2M | 49.6M | 168.9M | 177.3M | |
Depreciation And Amortization | 22.2M | 83.2M | 102M | 25.7M | 186M | 195.3M | |
Selling General Administrative | 482.6M | 544.2M | 684.1M | 867.2M | 1.0B | 1.1B | |
Income Before Tax | 104.2M | 225M | 173.9M | 390.8M | 710.4M | 745.9M | |
Total Other Income Expense Net | 80.1M | (38.1M) | (74.5M) | (1.5M) | (2M) | (2.1M) | |
Total Revenue | 1.5B | 1.9B | 2.4B | 2.9B | 3.6B | 3.8B | |
Gross Profit | 931.5M | 1.3B | 1.7B | 1.9B | 2.3B | 2.4B | |
Cost Of Revenue | 544.5M | 646.6M | 768M | 1.0B | 1.3B | 1.4B | |
Net Income From Continuing Ops | 101.1M | 493.6M | 154.7M | 341.2M | 541.5M | 568.6M | |
Net Income Applicable To Common Shares | 101.1M | 493.6M | 154.7M | 341.2M | 392.4M | 412.0M | |
Tax Provision | 3.1M | (268.6M) | 19.2M | 49.6M | 168.9M | 177.3M | |
Interest Income | 26.4M | 16.1M | 1.7M | 18M | 135M | 141.8M | |
Net Interest Income | (33.9M) | (68.6M) | (100.3M) | (18.6M) | 114.7M | 120.4M | |
Reconciled Depreciation | 48.7M | 67.1M | 102M | 155.9M | 186M | 95.1M |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving together with DexCom Stock
0.67 | NXL | Nexalin Technology | PairCorr |
Moving against DexCom Stock
0.77 | BBLG | Bone Biologics Corp Financial Report 20th of May 2024 | PairCorr |
0.74 | NUWE | Nuwellis Financial Report 14th of May 2024 | PairCorr |
0.73 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
0.73 | NAOV | NanoVibronix | PairCorr |
0.66 | HSTM | HealthStream | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.81 | Earnings Share 1.3 | Revenue Per Share 9.384 | Quarterly Revenue Growth 0.269 | Return On Assets 0.0641 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.